Literature DB >> 3854

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

I Creese, D R Burt, S H Snyder.   

Abstract

Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 3854     DOI： 10.1126/science.3854

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  377 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

Review 3.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

4.  Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency.

Authors:  T Ljungberg; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1979-02-28       Impact factor: 4.530

5.  Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses.

Authors:  Devin Mueller; Christian Bravo-Rivera; Gregory J Quirk
Journal:  Biol Psychiatry       Date:  2010-12-01       Impact factor: 13.382

Review 6.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

7.  The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

Authors:  Eunice Y Yuen; Xiangning Li; Jing Wei; Masakuni Horiguchi; Herbert Y Meltzer; Zhen Yan
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

8.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

9.  Subchronic oral administration of Benzo[a]pyrene impairs motor and cognitive behavior and modulates S100B levels and MAPKs in rats.

Authors:  Erica Santos Maciel; Regina Biasibetti; Ana Paula Costa; Paula Lunardi; Rebeca Vargas Antunes Schunck; Gabriela Curbeti Becker; Marcelo Dutra Arbo; Eliane Dallegrave; Carlos Alberto Gonçalves; Paulo H Nascimento Saldiva; Solange Cristina Garcia; Rodrigo Bainy Leal; Mirna Bainy Leal
Journal:  Neurochem Res       Date:  2014-03-02       Impact factor: 3.996

Review 10.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.